Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance

Standard treatment for advanced Prostate Cancer (PCa) consists of androgen deprivation therapy (ADT), but ultimately fails, resulting in the incurable phase of the disease: metastatic castration-resistant prostate cancer (mCRPC). Targeting PCa cells before their progression to mCRPC would greatly im...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Md Imtiaz, De Benedetti, Arrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992593/
https://www.ncbi.nlm.nih.gov/pubmed/35582542
http://dx.doi.org/10.20517/cdr.2021.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992593/
https://www.ncbi.nlm.nih.gov/pubmed/35582542
http://dx.doi.org/10.20517/cdr.2021.109

Ejemplares similares